Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Ther Clin Risk Manag. 2009 Feb;5(1):261-70. doi: 10.2147/tcrm.s3320. Epub 2009 Mar 26.
Anemia is a common complication of systemic anti-cancer treatment. In this context epoetin beta, like other erythropoiesis-stimulating agents (ESAs), has demonstrable efficacy in raising Hb concentration and reducing the requirement for red cell transfusion. Consequently ESA therapy has gained increasing prominence in the management of chemotherapy-related anemia. However, recent trial data have suggested a higher rate of thromboembolic events, enhanced tumor progression and reduced survival in some patients with cancer who receive ESA therapy. In response, regulatory authorities have mandated increasingly restrictive label changes. In light of these new developments we consider the current role of epoetin beta in the management of chemotherapy-related anemia.
贫血是全身性抗癌治疗的常见并发症。在这种情况下，促红细胞生成素β与其他红细胞生成刺激剂（ESAs）一样，在提高血红蛋白浓度和减少红细胞输注需求方面具有明显的疗效。因此，ESA 治疗在化疗相关性贫血的治疗中越来越受到重视。然而，最近的试验数据表明，接受 ESA 治疗的某些癌症患者的血栓栓塞事件发生率更高、肿瘤进展更快、生存率降低。作为回应，监管机构已强制要求对标签进行越来越严格的更改。有鉴于此，我们考虑促红细胞生成素β在化疗相关性贫血管理中的当前作用。
